Stephanie Offord
Family · Milwaukee, WINPI 1477736163
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $70,216 of the $115,734 with a category attached, or 60.7%. 13 manufacturers reported payments, led by Amgen at 43.3% of the total. Among family clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 222 payments — averaging $521.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$50K
- Biomarin Pharmaceutical Inc.$42K
- Sanofi$14K
- Amicus Therapeutics, Inc.$5K
- Chiesi USA, Inc.$2K
- Zevra Therapeutics Inc$1K
- plus $1K from 7 others
Across 89 payments — averaging $7276.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomarin Pharmaceutical Inc.$555K
- PTC Therapeutics, Inc.$93K
What the payments were for
- Consulting fees$27,24024%
- Speaking & faculty fees$70,21661%
- Travel & lodging$9,3618%
- Food & beverage$8,8878%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 57 | $50,138 |
| Biomarin Pharmaceutical Inc. | 112 | $41,737 |
| Sanofi | 25 | $14,138 |
| Amicus Therapeutics, Inc. | 9 | $5,369 |
| Chiesi USA, Inc. | 3 | $1,690 |
| Zevra Therapeutics Inc | 2 | $1,443 |
| PTC Therapeutics, Inc. | 4 | $464 |
| AstraZeneca | 5 | $374 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Illumina, Inc. | 1 | $123 |
| Mirum Pharmaceuticals, Inc. | 1 | $87 |
| Ultragenyx Pharmaceutical Inc. | 1 | $30 |
| Eton Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$115,734 in reported general payments places this provider in the 95th percentile of 1,273 family providers in Wisconsin.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FabrazymeAgalsidase Beta | 24 | $600,627 |
| PalynziqPegvaliase-Pqpz | 11 | $280,649 |
| Sapropterin Dihydrochloride | 25 | $215,252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiFabrazyme | $14,138 | $600,62724 claims |
| Biomarin Pharmaceutical Inc.Palynziq | $41,737 | $280,64911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,273 family providers in Wisconsin.
Other family in Milwaukee
- Tracy NelsonMilwaukee$24K
- Sarah EmmerichMilwaukee$15K
- Erin LassanskeMilwaukee$14K
- Katrina BaxterMilwaukee$13K
- Natalie KerberMilwaukee$12K
- Jenta AlexanderMilwaukee$12K
- Lileta WintMilwaukee$10K
- Mary Jane de JesusMilwaukee$10K
- Kelley BeltranMilwaukee$9K
- Angela GillMilwaukee$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.